Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 3, 2003, Pages 261-265

  Bauer, Sebastian ^a,e   Corless, Christopher L ^b   Heinrich, Michael C ^c,d   Dirsch, Olaf ^a   Antoch, Gerald ^a   Kanja, Jörg ^a   Seeber, Siegfried ^a   Schütte, Jochen ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Gastrointestinal stromal tumor; GIST; Imatinib; KIT immunonegativity

Indexed keywords

CD34 ANTIGEN; IMATINIB; TYROSINE KINASE RECEPTOR;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; ENZYME ACTIVITY; ENZYME INHIBITION; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE DELETION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; TREATMENT OUTCOME; TUMOR BIOPSY;

EID: 0344837699     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0564-x     Document Type: Article

References (12)

1. Apperley J (2002) A rationally designed, targeted tumor treatment approach: a phase II study of imatinib mesylate (Gleevec) in patients with life threatening diseases known to be associated with imatinib-sensitive tyrosine kinases. Proc Am Soc Clin Oncol 21:3a
2. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493-502
3. Corless CL, McGreevey L, Haley A, Town A, Heinrich M (2002) KIT mutations are common in incidental gastrointestinal stromal tumors one centimetre or less in size. Am J Pathol 160:1567-1572
4. Demetri GD, Rankin C, Fletcher C, Benjamin RS, Blanke C, Von Mehren M, Bramwell V, Maki RG, Blum R, Antman K, Baker L, Borden E (2002a) Phase III dose-randomized study of imatinib mesylate (gleevec, STI571) for GIST: intergroup S0033 early results. Proc Am Soc Clin Oncol 21:413a
5. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CDM, Joensuu H (2002b) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl J Med 347:472-480
6. Fletcher CDM, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459-465
7. Heinrich MC, Wait CL, Yee KWH, Griffith DJ (2001) STI571 inhibits the kinase activity of wild type and juxtamembrane c-kit mutants but not the exon 17 D816 V mutation associated with mastocytosis. Blood 96:173b
8. Heinrich MC, Corless CL, Blanke C, Demetri G, Joensuu H, von Mehren M, McGreevey L, Wait C, Griffith D, Chen C-J, Haley A, Kiese B, Druker B, Roberts P, Eisenberg B, Singer S, Silberman S, Dimitrijevic S, Fletcher C, Fletcher J (2002) KIT mutational status predicts clinical response to ST1571 in patients with metastatic gastrointestinal stromal tumors (GISTs). Proc Am Soc Clin Oncol 21:2a
9. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580
10. Johnson BE, Fisher B, Fisher T, Dunlop D, Rischin D, Silberman S, Kowalski M, Sayles D, Fletcher C, Salgia R, Delbaldo C, Le Chevalier T (2002) Phase II study of STI571 (Gleevec) for patients with small cell lung cancer. Proc Am Soc Clin Oncol 21:293a
11. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118-8121
12. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421-1423